A phase II study of vismodegib, a hedgehog (Hh) pathway inhibitor, combined with gemcitabine and nab-paclitaxel (nab-P) in patients (pts) with untreated metastatic pancreatic ductal adenocarcinoma (PDA)

被引：30
|
作者：
De Jesus-Acosta, Ana
O'Dwyer, Peter J.
Ramanathan, Ramesh K.
Von Hoff, Daniel D.
Maitra, Anirban
Rasheed, Zeshaan
Zheng, Lei
Rajeshkumar, N. V.
Le, Dung T.
Hoering, Antje
Bolejack, Vanessa
Yabuuchi, Shinichi
Laheru, Daniel A.
机构：
[1] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA
[2] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[3] Scottsdale HealthCare, Scottsdale, AZ USA
[4] Scottsdale Healthcare TGen, Virginia G Piper Canc Ctr Clin Trials, Scottsdale, AZ USA
[5] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[6] Johns Hopkins Univ, Baltimore, MD USA
[7] Canc Res & Biostat, Seattle, WA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 03期
关键词：
D O I：
10.1200/jco.2014.32.3_suppl.257
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
257
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase I/II trial of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma
    Weiss, Glen J.
    Waypa, Jordan
    Coats, Jessica
    Blaydorn, Lisa
    McGahey, Kayla
    Sangal, Ashish
    Whitehead, Robert P.
    Khemka, Vivek
    CANCER RESEARCH, 2017, 77
  • [22] Phase Ib Study of Ulixertinib Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma
    Grierson, Patrick M.
    Tan, Benjamin
    Pedersen, Katrina S.
    Park, Haeseong
    Suresh, Rama
    Amin, Manik A.
    Trikalinos, Nikolaos A.
    Knoerzer, Deborah
    Kreider, Brent
    Reddy, Anupama
    Liu, Jingxia
    Der, Channing J.
    Wang-Gillam, Andrea
    Lim, Kian-Huat
    ONCOLOGIST, 2023, 28 (02): : E115 - E123
  • [23] FOLFOX and nab-paclitaxel (nab-P) for advanced pancreatic cancer: A phase I study
    Safran, Howard
    Charpentier, Kevin
    Perez, Kimberly
    Mantripragada, Kalyan
    Austin, Trevor Clark
    Nadeem, Omar
    Lombardo, Alise
    Houlihan, Lindsay
    Fontes-Borts, Lucia
    Kolberg, Irene
    Mitchell, Kristen
    Rosati, Kayla
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [24] Interim results of a multicenter phase II trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC).
    Lacy, Jill
    Portales, Fabienne
    Hammel, Pascal
    Cid, Roberto A. Pazo
    Mozo, Jose Luis Manzano
    Kim, Edward Jae-hoon
    Dowden, Scot D.
    Borg, Christophe
    Sastre, Javier
    Bathini, Venu Gopal
    Terrebonne, Eric
    Lopez-Trabada, Daniel
    Rivera, Fernando
    Asselah, Jamil
    Damiani, Azzurra
    Hwang, Jimmy J.
    Ong, Teng Jin
    Nydam, Thom
    Li, Jack Shiansong
    Philip, Philip Agop
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [25] Cost-effectiveness of NALIRIFOX versus Nab-paclitaxel and gemcitabine in previously untreated metastatic pancreatic ductal adenocarcinoma
    Wenjie Liu
    Yuting Fang
    Chao Zhang
    Midan Xiang
    Lijuan Qi
    Aijiang Su
    Yongkun Sun
    BMC Gastroenterology, 25 (1)
  • [26] Expression of SPARC and response to nab-paclitaxel (nab-p) in patients (pts) with metastatic breast cancer (MBC)
    Schneeweiss, Andreas
    Aigner, Julia
    Smetanay, Katherina
    Schuetz, Florian
    Sohn, Christof
    Kriegsmann, Mark
    Jaeger, Dirk
    Zorn, Markus
    Bachinger, Andreas
    Sinn, Hans-Peter
    Marme, Frederik
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [27] Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma
    Ng, Kimmie
    Hendifar, Andrew
    Starodub, Alexander
    Chaves, Jorge
    Yang, Yingsi
    Koh, Brian
    Barbie, David
    Hahn, William C.
    Fuchs, Charles S.
    INVESTIGATIONAL NEW DRUGS, 2019, 37 (01) : 159 - 165
  • [28] Phase II LAPACT trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients with locally advanced pancreatic cancer (LAPC).
    Hammel, Pascal
    Lacy, Jill
    Portales, Fabienne
    Sobrero, Alberto F.
    Cid, Roberto A. Pazo
    Mozo, Jose Luis Manzano
    Mozo, Manzano
    Terrebonne, Eric
    Dowden, Scot D.
    Li, Jack Shiansong
    Ong, Teng Jin
    Nydam, Thom
    Philip, Philip Agop
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [29] HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab- Paclitaxel/Gemcitabine Versus Nab- Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma
    Hingorani, Sunil R.
    Zheng, Lei
    Bullock, Andrea J.
    Seery, Tara E.
    Harris, William P.
    Sigal, Darren S.
    Braiteh, Fadi
    Ritch, Paul S.
    Zalupski, Mark M.
    Bahary, Nathan
    Oberstein, Paul E.
    Wang-Gillam, Andrea
    Wu, Wilson
    Chondros, Dimitrios
    Jiang, Ping
    Khelifa, Sihem
    Pu, Jie
    Aldrich, Carrie
    Hendifar, Andrew E.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04) : 359 - +
  • [30] Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma
    Kimmie Ng
    Andrew Hendifar
    Alexander Starodub
    Jorge Chaves
    Yingsi Yang
    Brian Koh
    David Barbie
    William C. Hahn
    Charles S. Fuchs
    Investigational New Drugs, 2019, 37 : 159 - 165
12345